Celltrion’s Vegzelma (biosimilar, bevacizumab) Receives the US FDA’s Approval for the Treatment of Cancers
Shots:
- The US FDA has approved Vegzelma, a biosimilar to Avastin (bevacizumab) for 6 types of cancer i.e., mCRC, recurrent or metastatic nsq. NSCLC, recurrent GBM, metastatic RCC, persistent, recurrent, or metastatic cervical cancer; and EOC, fallopian tube, or PPC
- The approval was based on the totality of evidence incl. the P-III trial of Vegzelma in patients with metastatic or recurrent nsq. NSCLC. The results showed that the therapy was highly similar to the reference bevacizumab in terms of efficacy, safety & PK
- Vegzelma is the third oncology biosimilar to receive approval from the US FDA, following the approval of Truxima & Herzuma. Vegzelma was approved in the EU in August 2022 while UK & Japan in Sept 2022
Ref: Businesswire | Image: Celltrion
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
